Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
Cytoskeleton-focused company reports $2.2M Q4 revenues, provides oncology update
March 10th, 2005
Cytokinetics, Inc., (CYTK), for the fourth quarter of 2004, reported revenues from research and development (R&D) collaborations of $2.2 million. Net loss for the fourth quarter of 2004 was $11.8 million or $0.42 per share. As of December 31, 2004, cash, cash equivalents, restricted cash, and marketable securities totaled $116.2 million. "In 2004 we made progress in advancing our oncology development program. During the fourth quarter of 2004, in connection with our strategic alliance, GlaxoSmithKline initiated an additional phase II trial evaluating SB-715992 in the treatment of patients with advanced ovarian cancer. This trial...
Source: Women's Health Weekly (2005-03-10)
|
